<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Research — Santosh Gothwal</title>

    <link rel="stylesheet" href="assets/css/tailwind.css">

    <link href="https://fonts.googleapis.com/css2?family=Montserrat&display=swap" rel="stylesheet">

    <style>
        body {
            font-family: 'Montserrat', sans-serif;
        }
    </style>
</head>

<body class="flex flex-col min-h-screen">

    <!-- NAVBAR -->
    <div id="navbar"></div>

    <script src="common/include.js"></script>

    <script>
        loadHTML("navbar", "common/navbar.html").then(() => {

            const navToggle = document.getElementById('navToggle');
            const mobileMenu = document.getElementById('mobileMenu');
            const backdrop = document.getElementById('backdrop');

            function openMenu() {
                mobileMenu.classList.remove('scale-y-0', 'opacity-0');
                mobileMenu.classList.add('scale-y-100', 'opacity-100');
                backdrop.classList.remove('opacity-0', 'pointer-events-none');
            }

            function closeMenu() {
                mobileMenu.classList.add('scale-y-0', 'opacity-0');
                mobileMenu.classList.remove('scale-y-100', 'opacity-100');
                backdrop.classList.add('opacity-0', 'pointer-events-none');
            }

            navToggle?.addEventListener('click', () => {
                const isOpen = mobileMenu.classList.contains('scale-y-100');
                isOpen ? closeMenu() : openMenu();
            });

            backdrop?.addEventListener('click', closeMenu);
        });
    </script>

    <!-- MAIN -->
    <main class="pt-28 pb-20 px-6">
        <div class="max-w-5xl mx-auto">

            <h1 class="text-3xl md:text-4xl font-bold mb-10">
                Research Areas
            </h1>

            <div id="accordion" class="space-y-6">



                <!-- ===================================================== -->
                <!-- PROJECT 1 -->
                <!-- ===================================================== -->
                <section class="bg-[#EDEEE7] rounded-3xl shadow overflow-hidden">

                    <!-- Accordion Header -->
                    <button class="accordion-btn w-full flex justify-between items-center px-6 py-5 text-left
           hover:bg-black/5 transition">
                        <span class="font-semibold text-lg leading-snug">
                            1. Genetic trasmission into offsprings and suppresion of the genetic syndroms and cancer
                            predisposition
                        </span>
                        <span class="text-2xl transition-transform accordion-icon">+</span>
                    </button>

                    <!-- Accordion Content -->
                    <div class="accordion-panel hidden px-6 pb-8 space-y-8">


                        <!-- PROJECT 1 MAIN TEXT (paper style like screenshot) -->
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900">

                            Meiosis is a specialized germ cell division essential for generating haploid gametes,
                            such as sperm and eggs in humans. Defects in meiosis can result in infertility,
                            genetic syndromes and increased cancer risk in offspring (Tables 1–3). During my doctoral
                            studies at Osaka University, Japan, I investigated Spo11-dependent DNA double-strand break
                            (DSB) formation along the meiotic chromosomes using budding yeast as a model.
                            Spo11-mediated DSBs initiate meiotic recombination, enabling chiasma formation and genetic
                            diversity in gametes. Defects in any of these steps can lead defective gamete formation
                            causing trisomy’s, monosomies and nullisomic (Table 1-3-hyperlink).

                        </p>

                        <!-- HIGHLIGHT STATEMENT BOX (blue callout like screenshot) -->
                        <div id="figure_pro1"
                            class="mt-6 bg-[#0F5E7A] border-2 border-[#083E52] rounded-2xl px-5 py-4 shadow-md">

                            <p class="text-white text-sm sm:text-base font-semibold leading-relaxed">

                                My work identified Paf1C as a genome-wide gatekeeper that directs meiotic DNA breaks
                                to safe recombination hotspots while preventing chromosomal instability.

                            </p>

                        </div>
                        <!-- =============================== -->
                        <!-- PROJECT 1 — TWO FIGURES (NO TEXT) -->
                        <!-- =============================== -->
                        <div class="mt-8 flex justify-center w-full">

                            <div class="grid grid-cols-1 md:grid-cols-2 gap-8 max-w-5xl w-full">

                                <!-- FIGURE A -->
                                <div class="relative aspect-[4/3]">
                                    <img src="images/projects/project1_1.png"
                                        class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition cursor-zoom-in"
                                        alt="Project 1 Figure A" onclick="openZoom(this.src)" />
                                </div>

                                <!-- FIGURE B -->
                                <div class="relative aspect-[4/3]">
                                    <img src="images/projects/project1_2.png"
                                        class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition cursor-zoom-in"
                                        alt="Project 1 Figure B" onclick="openZoom(this.src)" />
                                </div>

                            </div>

                        </div>
                        <!-- =============================== -->
                        <!-- PROJECT 1 MAIN PARAGRAPH -->
                        <!-- =============================== -->
                        <p class="mt-8 text-sm sm:text-base leading-relaxed text-gray-900">

                            I demonstrated that RNA polymerase II elongation complex (Paf1C) promotes Spo11-dependent
                            DSB formation at meiotic recombination hotspots while Paf1C suppresses meiotic DSBs
                            at cold spots
                            (<a href="#table_pro1" class="text-blue-700 underline hover:text-blue-900 transition">
                                Gothwal et al., <em>Genetics</em>, 2016; Tables 1–3
                            </a>).
                            Paf1C loss reduced Mre11 and Rad51/Dmc1 assembly on the meiotic chromosomes.
                            Loss of Paf1C resulted in the emergence of ~180 de novo meiotic hotspots
                            (<a href="#figure_pro1" class="text-blue-700 underline hover:text-blue-900 transition">
                                Figure
                            </a>),
                            including repetitive DNA regions residing near telomeric and centromeric regions.
                            Recombination of repetitive DNA sequences is a major cause of non-allelic homologous
                            recombination (NAHR) and chromosomal rearrangements
                            (<a href="#table_pro1" class="text-blue-700 underline hover:text-blue-900 transition">
                                Tables 1-3
                            </a>),
                            therefore Paf1C can suppress NAHR during meiosis.

                        </p>
                        <!-- =============================== -->
                        <!-- PROJECT 1 — FINAL PARAGRAPH -->
                        <!-- =============================== -->
                        <p id="table_pro1" class="text-sm sm:text-base leading-relaxed text-gray-900 mt-6">

                            In cancer biology context, mammalian homologues of Paf1C, SET1/COMPASS complexes such as
                            <strong>MLL1/3</strong> are frequently overexpressed in tumors such as in childhood
                            leukemia.
                            Building on this conserved biology, I am currently investigating <strong>WDR5</strong>, a
                            core
                            MLL1 complex member in humans, which is highly expressed in several solid cancers.
                            My future studies aim to understand the dysregulated function of histone
                            methyltransferases in cancers.

                        </p>

                        <!-- =============================== -->
                        <!-- TABLE 1 TITLE -->
                        <!-- =============================== -->
                        <h3 class="text-sm sm:text-base font-semibold text-orange-700 mt-6 mb-3">
                            Table 1: Genetic Syndromes Caused by Meiotic Recombination Defects and NAHR
                        </h3>

                        <!-- =============================== -->
                        <!-- TABLE 1 (Responsive + Connected) -->
                        <!-- =============================== -->
                        <div class="overflow-x-auto rounded-xl border border-gray-400 bg-white shadow-sm">

                            <table class="w-full text-sm text-left border-collapse">

                                <!-- Header -->
                                <thead class="bg-gray-100">
                                    <tr>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Gene(s)
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Recombination Mechanism Defect
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Syndrome / Phenotype
                                        </th>
                                    </tr>
                                </thead>

                                <!-- Body -->
                                <tbody>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            ATM
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Defective DSB signaling & meiotic crossover control
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Ataxia-telangiectasia
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            ATR
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Impaired DSB repair & replication stress response
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Seckel syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            NBN (NBS1)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Defective homologous recombination & DSB repair
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Nijmegen breakage syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            BLM
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Excess sister chromatid exchange, faulty crossover resolution
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Bloom syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            WRN
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Defective recombination & telomere maintenance
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Werner syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            FANCA–FANCN
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Interstrand crosslink repair failure during meiosis
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Fanconi anemia
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            DMC1
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Failed strand invasion during meiotic recombination
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Ovarian failure, azoospermia
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            MSH4 / MSH5
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Defective crossover stabilization
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Primary ovarian insufficiency
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            SYCP2 / SYCP3
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Defective synaptonemal complex formation
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Infertility, aneuploidy
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            TEX11
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Abnormal meiotic recombination & synapsis
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Non-obstructive azoospermia
                                        </td>
                                    </tr>

                                </tbody>
                            </table>

                        </div>
                        <!-- =============================== -->
                        <!-- TABLE 2 TITLE -->
                        <!-- =============================== -->
                        <h3 class="text-sm sm:text-base font-semibold text-orange-700 mt-8 mb-3">
                            Table 2: Mediated Microdeletion / Microduplication Syndromes
                        </h3>

                        <!-- =============================== -->
                        <!-- TABLE 2 (Responsive) -->
                        <!-- =============================== -->
                        <div class="overflow-x-auto rounded-xl border border-gray-400 bg-white shadow-sm mb-10">

                            <table class="w-full text-sm text-left border-collapse">

                                <!-- Header -->
                                <thead class="bg-gray-100">
                                    <tr>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Gene / Region
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Mechanism
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Syndrome
                                        </th>
                                    </tr>
                                </thead>

                                <!-- Body -->
                                <tbody>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            22q11.2
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR between LCRs
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            DiGeorge / Velocardiofacial
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            7q11.23 (ELN)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR-mediated deletion
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Williams–Beuren syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            15q11–q13
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR + imprinting
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Prader–Willi syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            15q11–q13
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR + imprinting
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Angelman syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            17p11.2
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR deletion
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Smith–Magenis syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            17p11.2
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR duplication
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Potocki–Lupski syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            PMP22
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR duplication
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Charcot–Marie–Tooth 1A
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            PMP22
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR deletion
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            HNPP
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            11p13
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR deletion
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            WAGR syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            17p13.3
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            NAHR deletion
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Miller–Dieker syndrome
                                        </td>
                                    </tr>

                                </tbody>
                            </table>
                        </div>


                        <!-- =============================== -->
                        <!-- TABLE 3 TITLE -->
                        <!-- =============================== -->
                        <h3 class="text-sm sm:text-base font-semibold text-orange-700 mt-8 mb-3">
                            Table 3: Short-Homology NAHR / Microhomology-Mediated Rearrangement
                        </h3>

                        <!-- =============================== -->
                        <!-- TABLE 3 (Responsive) -->
                        <!-- =============================== -->
                        <div class="overflow-x-auto rounded-xl border border-gray-400 bg-white shadow-sm">

                            <table class="w-full text-sm text-left border-collapse">

                                <!-- Header -->
                                <thead class="bg-gray-100">
                                    <tr>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Gene
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Mechanism
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Syndrome
                                        </th>
                                    </tr>
                                </thead>

                                <!-- Body -->
                                <tbody>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            PLP1
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Microhomology-mediated duplication
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Pelizaeus–Merzbacher disease
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            MECP2
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Complex duplication via short homologies
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            MECP2 duplication syndrome
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            DMD
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Microhomology-mediated deletions
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Duchenne / Becker MD
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            F8
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Intron inversion via recombination
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Hemophilia A
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            HBA1 / HBA2
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Unequal crossover on short homology
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            α-thalassemia
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold italic">
                                            NSD1
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Non-recurrent microdeletion
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Sotos syndrome
                                        </td>
                                    </tr>

                                </tbody>
                            </table>
                        </div>

                    </div>

                </section>


                <!-- ===================================================== -->
                <!-- PROJECT 2 -->
                <!-- ===================================================== -->
                <section class="bg-[#EDEEE7] rounded-3xl shadow overflow-hidden">

                    <!-- Accordion Header -->
                    <button class="accordion-btn w-full flex justify-between items-center px-6 py-5 text-left
           hover:bg-black/5 transition">
                        <span class="font-semibold text-lg leading-snug">
                            2. Antibody Class-Switch Recombination and B-lymphomagenesis
                        </span>
                        <span class="text-2xl transition-transform accordion-icon">+</span>
                    </button>

                    <!-- Accordion Content -->
                    <div class="accordion-panel hidden px-6 pb-8 space-y-8">


                        <!-- PROJECT 2 MAIN PARAGRAPH (paper-style, mobile-friendly) -->
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900">

                            In my postdoctoral training at Kyoto University under the supervision of Prof. Tasuku Honjo
                            (Nobel Laureate, 2018), I investigated the role of the histone acetyl-reader protein BRD2 in
                            antibody class switch recombination (CSR). Activation-Induced Cytidine Deaminase (AID)
                            induces
                            DNA breaks at the immunoglobulin (<em>Ig</em>) locus for CSR, which are mainly repaired by
                            non-homologous end joining (NHEJ). AID off-targeting can lead to several forms of B-cell
                            lymphomas
                            (<a href="#table_pro2" class="text-blue-700 underline hover:text-blue-900 transition"> Table
                            </a>).

                            I demonstrated that BRD2 promotes NHEJ at the <em>Ig</em> locus by facilitating KU70/80
                            assembly,
                            while suppressing RAD51 assembly and, consequently, homologous recombination (HR). BRD2 also
                            suppresses microhomology-mediated end joining (MMEJ)
                            (<a href="https://doi.org/10.1093/nar/gkae204"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Gothwal et al., 2024, Nucleic Acids Research
                            </a>).

                            BRD2 coordinates with the cohesin loader NIPBL and CTCF to promote NHEJ during CSR.
                            Intriguingly,
                            NIPBL knockdown—mutations of which are associated with
                            <a href="https://en.wikipedia.org/wiki/Cornelia_de_Lange_syndrome"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Cornelia de Lange syndrome
                            </a> — also impairs NHEJ and CSR, suggesting broader links between chromatin structure and
                            epigenetic regulation in humoral immunity.

                            My work provided new insights into how BRD2, together with chromosome structural proteins
                            such
                            as NIPBL, maintains genome integrity during antibody diversification while limiting
                            oncogenic
                            translocations.

                        </p>

                        <!-- FIGURE ROW (matches screenshot positioning) -->
                        <div class="grid grid-cols-2 gap-6 items-start max-w-4xl mx-auto">


                            <!-- FIGURE A -->
                            <div class="relative aspect-[4/3]">
                                <img src="images/projects/project2_1.png"
                                    class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                    alt="Project 4 figure A" />
                            </div>

                            <!-- FIGURE B -->
                            <div class="relative aspect-[4/3]">
                                <img src="images/projects/project2_2.png"
                                    class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                    alt="Project 4 figure B" />
                            </div>
                        </div>

                        <!-- FUTURE DIRECTION PARAGRAPH -->
                        <p id="table_pro2" class="text-sm sm:text-base leading-relaxed text-gray-900 mb-6">
                            In the future research, I will continue exploring the epigenetic regulators in the antibody
                            class
                            switch recombination. The novel regulators of NHEJ and MMEJ and help understand the
                            mechanism of
                            genome-translocations arising during the antibody diversification in humans.
                        </p>

                        <!-- TABLE TITLE -->
                        <h3 class="text-sm sm:text-base font-semibold text-blue-800 mb-3">
                            Table 1 (List of B-lymphoma arising during the AID activation)
                        </h3>

                        <!-- TABLE (Mobile Responsive Scroll) -->
                        <div class="overflow-x-auto rounded-xl border border-gray-400 bg-white shadow-sm">
                            <table class="w-full text-sm text-left border-collapse">

                                <!-- Header -->
                                <thead class="bg-gray-100">
                                    <tr>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Lymphoma Type
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Primary Translocation
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            <em>Ig</em> Partner
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Oncogene Partner
                                        </th>
                                    </tr>
                                </thead>

                                <!-- Body -->
                                <tbody>
                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Burkitt Lymphoma
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            t(8;14), t(2;8), t(8;22)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IGH, IGK, IGL
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            MYC
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Follicular Lymphoma
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            t(14;18)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IGH
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            BCL2
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2">
                                            DLBCL (GCB subtype)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IgH/IgL–BCL6
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IGH/IGL
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            BCL6
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            DLBCL with MYC rearrangement
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IgH/IgL–MYC
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IGH/IGL
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            MYC
                                        </td>
                                    </tr>

                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2">
                                            High-grade B-cell lymphoma (DH/TH)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            Ig translocations involving MYC, BCL2, BCL6
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 italic">
                                            IGH/IGL/IGK
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Multiple
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>


                    </div>
                </section>

                <!-- ===================================================== -->
                <!-- PROJECT 3 -->
                <!-- ===================================================== -->
                <section class="bg-[#EDEEE7] rounded-3xl shadow overflow-hidden">

                    <!-- Accordion Header -->
                    <button
                        class="accordion-btn w-full flex justify-between items-center px-6 py-5 text-left hover:bg-black/5 transition">

                        <span class="font-semibold text-base sm:text-lg leading-snug">
                            3. Regulation of G-protein coupled receptors in the tumor suppresion and germinal center
                            reactions
                        </span>

                        <span class="text-2xl transition-transform accordion-icon">+</span>
                    </button>

                    <!-- Accordion Content -->
                    <div class="accordion-panel hidden px-6 pb-8 space-y-8">

                        <!-- MAIN PARAGRAPH (paper-style with DOI hyperlink) -->
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900">

                            In my independent research at Kyoto University Hospital, and as an assistant
                            professor at Cancer Research Institute, Kanazawa University, Japan, I investigated the
                            mechanisms suppressing the B-lymphomagenesis. I found that B-lymphoma cells specifically
                            start express the CXCL13 ligand while normal B cells do not express the CXCL13 ligand
                            (<a href="https://doi.org/10.1101/2024.08.31.609994" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">Gothwal et al., 2024
                            </a>).

                        </p>

                        <p class="text-sm sm:text-base leading-relaxed text-gray-900 mt-4">

                            I hypothesized that intracellular CXCL13 ligand expression in B-cell lymphomas can impair
                            their migration toward the light zone by promoting internalization of the CXCR5 receptor,
                            a G-protein–coupled receptor for CXCL13. This impaired migration to the light zone can
                            prevent affinity maturation due to restricted entry into the light zone, as follicular
                            dendritic cells provide essential survival signals required for B-cell affinity maturation
                            in this compartment. This selective adaptation of CXCL13 expression in germinal
                            center–derived B-cell lymphomas may serve as a key tumor-suppressive mechanism.

                        </p>

                        <!-- Image Grid -->
                        <div class="flex justify-center">
                            <div class="grid grid-cols-1 sm:grid-cols-2 gap-6 max-w-4xl w-full">

                                <!-- Figure A -->
                                <div class="relative aspect-[4/3]">
                                    <span class="absolute top-3 left-3 bg-white/90 text-gray-900 border border-gray-300
                   text-xs font-semibold px-3 py-1 rounded-md shadow-sm">
                                        A
                                    </span>

                                    <img src="images/projects/project3_1.png"
                                        class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                        alt="Spo11-dependent meiotic recombination hotspots regulated by Paf1C" />
                                </div>

                                <!-- Figure B -->
                                <div class="relative aspect-[4/3]">
                                    <span class="absolute top-3 left-3 bg-white/90 text-gray-900 border border-gray-300
                   text-xs font-semibold px-3 py-1 rounded-md shadow-sm">
                                        B
                                    </span>

                                    <img src="images/projects/project3_2.png"
                                        class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                        alt="Altered chromosome axis markers Rec8 and Hop1 in paf1 mutant" />
                                </div>

                            </div>
                        </div>

                        <!-- FIGURE CAPTION CARD (paper-style, mobile optimized) -->
                        <div class="bg-white rounded-2xl
         p-4 sm:p-5
         text-[11px] sm:text-sm
         leading-snug sm:leading-relaxed
         text-gray-700
         shadow-sm space-y-3">

                            <p>
                                <strong>(A)</strong>
                                The mechanims of CXCL13 expresion in the B-lymphomas is driven by the Distal enhancer
                                located nearly 400 kb upstream of CXCL13 promoter. This expresion of CXCL13 is
                                suppressed
                                by the DNA methylation and DNA-methylation binding protein MBD1. In the B-lymphomas, the
                                internal CXCL13 leads to CXCR5-receptor internalization, leading to the reduction of the
                                GC exit.
                            </p>

                            <p>
                                <strong>(B)</strong>
                                Model of GC derived B-lymphoma elimination in the GC reaction. The schematic of germinal
                                center reaction. B cells undergo Class switch recombination and Somatic hypermutation,
                                Antibody isotypes are generated. However, AID induced DSBs can often undergo non-Ig
                                locus,
                                leading to chromosomal translocations, such as IgH-Myc, IgH-Bcl6, making B-lymphoma
                                precursors. These precursors start making the internal CXCL13, leading to the B-lymphoma
                                confinement in the DZ, thus elimination of B-lymphomagenesis is regulated during the GC
                                reaction.
                            </p>

                        </div>
                        <!-- MAIN PARAGRAPH (paper-style, mobile small) -->
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900">

                            Mechanistically I demonstrated that intrinsic <em>CXCL13</em> expression in B-lymphomas is
                            driven by a
                            distal super-enhancer located on the <em>CCNG2</em> locus, revealing a previously unknown
                            mechanism
                            of <em>CXCL13</em> expression in B-lymphomas
                            (<a href="https://doi.org/10.1101/2024.08.31.609994" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">Gothwal et al., 2024
                            </a>).

                            Further, I demonstrated that aberrant CXCL13–CXCR5 signaling in solid tumors (e.g., HCT116,
                            HepG2)
                            enhances expression of cell cycle regulators (<em>PTP4A1</em>), metastatic receptors
                            (<em>CCR7</em>),
                            and ubiquitin ligases involved in the p53 degradation, contributing to drug resistance via
                            p53
                            dysregulation. This approach led to the identification of CCR7, PTP4A1, and p53-specific
                            ubiquitin
                            ligases as novel therapeutic targets, particularly in the cancers exhibiting co-expression
                            of CXCL13
                            ligand CXCR5. My future research direction will be exploring the therapeutic efficacy of
                            inhibiting
                            the CXCR5–CXCL13 axis targets such as <em>PTP4A1</em>, combination with existing
                            chemotherapies and
                            immunotherapies
                            (<a href="https://doi.org/10.1101/2024.08.31.609994" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">Gothwal et al., 2024
                            </a>).

                        </p>


                    </div>
                </section>


                <!-- ===================================================== -->
                <!-- PROJECT 4 -->
                <!-- ===================================================== -->
                <section class="bg-[#EDEEE7] rounded-3xl shadow overflow-hidden">

                    <button class="accordion-btn w-full flex justify-between items-center px-6 py-5 text-left
         hover:bg-black/5 transition">
                        <span class="font-semibold text-lg">
                            4. Epigenetic regulation of BCL6 translocations and implications in cancer target therapies
                        </span>
                        <span class="text-2xl transition-transform">+</span>
                    </button>
                    <div class="accordion-panel hidden px-6 pb-8 space-y-5">

                        <!-- MAIN TEXT BLOCK (paper-style like screenshot) -->
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900 text-justify">

                            <em>BCL6</em> is an oncoprotein, that suppresses p53 response, DNA damage signaling,
                            inflammatory and apoptotic signalling. <em>BCL6</em>-translocations are observed in
                            31% of diffuse large B-cell lymphoma (DLBCL) and in other solid cancers
                            (<a href="https://doi.org/10.1101/2025.03.13.643172" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Gothwal et al., 2025
                            </a>).
                            <em>BCL6</em> overexpression is a predominant feature in these tumors causing
                            therapeutic failure.

                            DNA-CpG methylation-binding protein 1 (<em>MBD1</em>) was one of the factors
                            identified from my recently developed screening for identification of novel tumor
                            suppressors using the <em>GC</em> derived B-lymphoma cells
                            (<a href="https://doi.org/10.1101/2024.12.19.628635" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">Gothwal et al., 2024
                            </a>).

                            <em>BCL6</em> translocation hotspot harbors the conserved CpG methylation sites,
                            I hypothesized that <em>MBD1</em> might suppress the <em>BCL6</em> translocation
                            via its CpG methylation binding to <em>BCL6</em> promoter.

                            Functional analysis of <em>MBD1</em> revealed that <em>MBD1</em> suppresses
                            genomic instabilities at the <em>BCL6</em> locus, possibly suppressing the
                            <em>BCL6</em> translocation
                            (<a href="https://doi.org/10.1101/2025.03.13.643172" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">Gothwal et al., 2025
                            </a>).

                            Furthermore, <em>MBD1</em> depletion sensitized Raji cells to HU, gemcitabine,
                            and etoposide, and <em>MBD1</em>-depeleted cells showed reduced tumorigenicity
                            in the mouse xenograft model
                            (<a href="https://doi.org/10.1101/2025.03.13.643172" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">Gothwal et al., 2025
                            </a>).

                            These highlight the potential of <em>MBD1</em> inhibition as a novel target
                            chemotherapy in cancers exhibiting treatment failure against the chemotherapeutic
                            drugs targeting the DNA replication.

                        </p>


                        <!-- FIGURE ROW (matches screenshot positioning) -->
                        <div class="grid grid-cols-2 gap-6 items-start max-w-4xl mx-auto">


                            <!-- FIGURE A -->
                            <div class="relative aspect-[4/3]">
                                <span
                                    class="absolute top-3 left-3 z-10 bg-black/70 text-white text-sm font-semibold px-3 py-1 rounded-md">
                                    A
                                </span>
                                <img src="images/projects/project4_1.png"
                                    class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                    alt="Project 4 figure A" />
                            </div>

                            <!-- FIGURE B -->
                            <div class="relative aspect-[4/3]">
                                <span
                                    class="absolute top-3 left-3 z-10 bg-black/70 text-white text-sm font-semibold px-3 py-1 rounded-md">
                                    B
                                </span>
                                <img src="images/projects/project4_2.png"
                                    class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                    alt="Project 4 figure B" />
                            </div>
                        </div>

                        <!-- CAPTION STRIP (journal-style) -->
                        <div class="border border-gray-400 bg-white px-4 py-2 text-[11px] leading-snug text-gray-900">

                            <p class="font-semibold mb-1">
                                MBD1 limits B cell lymphoma development and preserves genomic stability.
                            </p>

                            <p>
                                <strong>(A)</strong> Human Raji B cell lymphoma xenografts in nude mice exhibit reduced
                                tumor growth following MBD1 depletion, indicating a tumor-suppressive role for MBD1.
                            </p>

                            <p class="mt-1">
                                <strong>(B)</strong> Proposed model illustrating the role of MBD1 in regulating germinal
                                center (GC)-derived B cell lymphomas and maintaining genomic stability at the BCL6 locus
                                (adapted from Gothwal et al., 2024). Under genotoxic stress, MBD1 suppresses BCL6
                                expression
                                in B cells, potentially limiting BCL6-dependent lymphomagenesis in GCs. In parallel,
                                MBD1
                                fine-tunes IRF4 regulation to support proper plasma cell differentiation, ensuring the
                                fidelity and functional quality of the GC response.
                            </p>

                        </div>
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900 text-justify">

                            Moving forward, I will investigate how <strong>MBD1 or other transcriptional
                                silencers sensitize cancer cells under the DNA replication stress</strong>. This will
                            focus on
                            investigating the <strong>transcription–replication conflicts and DNA replication
                                stress–associated events</strong> that arise in the <strong>absence of MBD1</strong>.
                            Ultimate goal
                            of the study will be in elucidating the <strong>mechanisms of synthetic lethality</strong>
                            induced by <em>MBD1</em> depletion with combination of Poly (ADP-ribose) Polymerase
                            (PARP) inhibitors in <em>BRCA1/2</em> deficient cancers.

                        </p>


                    </div>

                </section>


                <!-- ===================================================== -->
                <!-- PROJECT 5 -->
                <!-- ===================================================== -->
                <section class="bg-[#EDEEE7] rounded-3xl shadow overflow-hidden">

                    <!-- Accordion Header -->
                    <button class="accordion-btn w-full flex justify-between items-center px-6 py-5 text-left
           hover:bg-black/5 transition">
                        <span class="font-semibold text-lg leading-snug">
                            5. Chemotherapeutic target development using Germinal center derived B-Cell Lymphoma
                        </span>
                        <span class="text-2xl transition-transform accordion-icon">+</span>
                    </button>

                    <!-- Accordion Content -->
                    <div class="accordion-panel hidden px-6 pb-8 space-y-8">

                        <div class="space-y-6">

                            <!-- Main Paragraph -->
                            <p class="text-sm sm:text-base leading-relaxed text-gray-900">
                                My original research hypothesis is influenced by germinal center (GC) biology.
                                The GC reaction is a central process in the humoral immune response, enabling
                                B cells to produce high-affinity antibodies in response to antigenic stimulation.
                                Upon antigenic stimulation, GC B cells upregulate two key regulators: BCL6,
                                which promotes B-cell survival, and activation-induced cytidine deaminase (AID).
                                AID activity at the immunoglobulin (<em>Ig</em>) locus is essential for somatic
                                hypermutation and class-switch recombination; however, if AID is off-targeted
                                to non-<em>Ig</em> loci such as <em>MYC</em> and <em>BCL6</em>, it can result in
                                chromosomal translocations, which are hallmarks of Burkitt’s lymphoma and
                                diffuse large B-cell lymphoma (DLBCL), respectively. In addition, several other
                                forms of B-cell lymphomas can be generated at various stages of GC B-cell development
                                (Table 1).
                            </p>

                            <!-- Hypothesis Highlight Line -->
                            <p
                                class="text-sm sm:text-base italic text-orange-600 text-center font-semibold leading-relaxed">
                                My hypothesis “Germinal centers (GCs) B cells possess strong tumor-suppressive
                                mechanisms that can be reactivated in GC-derived B-lymphomas by GC-like genotoxic
                                stress.”
                            </p>

                            <!-- ===================== -->
                            <!-- TWO FIGURES SIDE BY SIDE -->
                            <!-- ===================== -->
                            <div class="flex justify-center w-full">

                                <div class="grid grid-cols-1 md:grid-cols-2 gap-6 max-w-5xl w-full">

                                    <!-- FIGURE A -->
                                    <div class="relative aspect-[4/3]">
                                        <span
                                            class="absolute top-3 left-3 z-10 bg-black/70 text-white text-sm font-semibold px-3 py-1 rounded-md">
                                            A
                                        </span>
                                        <img src="images/projects/project5_1.png"
                                            class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                            alt="Project 4 figure A" />
                                    </div>

                                    <!-- FIGURE B -->
                                    <div class="relative aspect-[4/3]">
                                        <span
                                            class="absolute top-3 left-3 z-10 bg-black/70 text-white text-sm font-semibold px-3 py-1 rounded-md">
                                            B
                                        </span>
                                        <img src="images/projects/project5_2.png"
                                            class="w-full h-full object-contain rounded-2xl shadow-md hover:shadow-lg transition"
                                            alt="Project 4 figure B" />
                                    </div>

                                </div>
                            </div>

                            <!-- ===================== -->
                            <!-- FULL-WIDTH CAPTION BOX -->
                            <!-- ===================== -->
                            <div
                                class="bg-white border border-gray-400 rounded-xl p-4 text-xs sm:text-sm leading-snug text-gray-800">

                                <p><strong>(A)</strong> The schematic of germinal center reaction showing activated B
                                    cells undergoing
                                    somatic hypermutation and class switch recombination can undergo the
                                    differentiation,
                                    forming the memory and plasma B cells. Defective transformation in activated B cells
                                    at the various stages in GC can lead to variety of lymphomas including the Mantle
                                    cell
                                    lymphoma (MCL), Burkitt’s lymphoma (BL), Follicular lymphoma (FL), diffuse large B
                                    cell
                                    lymphoma (DLBCL), chronic lymphocytic leukemia (B-CLL), and multiple myelomas (MM).
                                    <br><br>
                                    <strong>(B)</strong> Identification of alerted genes in Hydroxyurea treated Raji
                                    cells for the
                                    development of novel cancer therapeutic targets. RNA-seq data is shown.
                                    Thy-Noc represents the group for thymidine and nocodazole treated cells as control
                                    group.
                                </p>

                            </div>


                        </div>
                        <p class="text-sm sm:text-base leading-relaxed text-gray-900">

                            Inspired with GC biology and to identify tumor suppressor mechanisms from GC B cells,
                            I utilized GC-derived B-cell lymphomas, Raji cells (Burkitt’s lymphoma) as a substrate.
                            I treated Raji cells with hydroxyurea (HU) to mimic replication stress experienced by
                            GC B cells followed by single-cell RNA sequencing and H3K4me3 chromatin
                            immunoprecipitation (ChIP), a mark of transcriptionally active promoters.

                            This approach allowed me to identify altered genes including epigenetic factors such as
                            <strong>ATAD2</strong>, <strong>ATAD5</strong>, zinc finger proteins,
                            E2/E3 ubiquitin ligases, DNA repair genes, and G-protein–coupled receptors,
                            suggesting druggable chemotherapeutic targets were also identified from the screening
                            (<a href="https://doi.org/10.1101/2024.12.19.628635" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Gothwal et al., 2024
                            </a>).

                            One altered factor was MBD1, whose functional analysis revealed its significance in
                            tumor suppression and the prevention of genomic instabilities on the
                            <em>BCL6</em>-translocation hotspot
                            (<a href="https://doi.org/10.1101/2025.03.13.643172" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Gothwal et al., 2025
                            </a>).

                            This validates my screen for identification of novel tumor suppressors.
                            My future research will focus on analyzing more factors from this screen
                            (<a href="https://doi.org/10.1101/2024.12.19.628635" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Gothwal et al., 2024
                            </a>)
                            and explore their therapeutic potential for hematological and solid cancer treatments.

                        </p><!-- =============================== -->
                        <!-- TABLE 1 TITLE -->
                        <!-- =============================== -->
                        <h3 class="text-sm sm:text-base font-semibold text-orange-700 mt-6 mb-3">
                            Table 1: List of key germinal center derived B-lymphomas
                        </h3>

                        <!-- =============================== -->
                        <!-- TABLE 1 (Responsive + Connected) -->
                        <!-- =============================== -->
                        <div class="overflow-x-auto rounded-xl border border-gray-400 bg-white shadow-sm">

                            <table class="w-full text-sm text-left border-collapse">

                                <!-- Header -->
                                <thead class="bg-gray-100">
                                    <tr>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Disease
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Cell of Origin
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Stage Relative to Germinal Center
                                        </th>
                                        <th class="border border-gray-400 px-3 py-2 font-semibold">
                                            Key Features Supporting Origin
                                        </th>
                                    </tr>
                                </thead>

                                <!-- Body -->
                                <tbody>

                                    <!-- Row 1 -->
                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Mantle Cell Lymphoma (MCL)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Naïve mature B cell (mantle zone B cell)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Pre-Germinal Center
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            IgM/IgD, SOX11, usually <em>unmutated</em> or minimally mutated IgVH
                                        </td>
                                    </tr>

                                    <!-- Row 2 -->
                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Follicular Lymphoma (FL)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Germinal center B cell (centrocyte/centroblast)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Germinal Center
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            CD10⁺, BCL6⁺, <em>mutated</em> IgVH, GC gene expression profile
                                        </td>
                                    </tr>

                                    <!-- Row 3 -->
                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Diffuse Large B-Cell Lymphoma (DLBCL)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Heterogeneous: GC B cell or post-GC B cell
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            GC or post-GC (depends on subtype)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            GCB subtype vs ABC subtype (cell-of-origin classification)
                                        </td>
                                    </tr>

                                    <!-- Row 4 -->
                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Multiple Myeloma (MM)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Long-lived plasma cell
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Post-Germinal Center
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Fully differentiated plasma cell, heavily mutated Ig genes
                                        </td>
                                    </tr>

                                    <!-- Row 5 -->
                                    <tr>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            B-Chronic Lymphocytic Leukemia (B-CLL)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Antigen-experienced B cell (memory-like)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2 font-semibold">
                                            Pre- or Post-GC (two subtypes)
                                        </td>
                                        <td class="border border-gray-400 px-3 py-2">
                                            Mutated vs unmutated IgVH defines GC experience
                                        </td>
                                    </tr>

                                </tbody>
                            </table>

                        </div>


                    </div>
                </section>

                <!-- ===================================================== -->
                <!-- PROJECT 6 -->
                <!-- ===================================================== -->
                <section class="bg-[#EDEEE7] rounded-3xl shadow overflow-hidden">

                    <!-- Accordion Header -->
                    <button class="accordion-btn w-full flex justify-between items-center px-6 py-5 text-left
         hover:bg-black/5 transition">

                        <span class="font-semibold text-lg leading-snug">
                            6. Immune dysregulation in Li-Fraumeni syndrome patients
                        </span>

                        <span class="text-2xl transition-transform accordion-icon">+</span>
                    </button>

                    <!-- Accordion Content -->
                    <div class="accordion-panel hidden px-6 pb-8 space-y-8">

                        <!-- Paragraph 1 -->
                        <p class="text-xs sm:text-base leading-relaxed text-gray-900">
                            Li-Fraumeni syndrome is a hereditary cancer predisposition disorder caused by germline
                            <strong><em>TP53</em></strong> mutations that often confer gain-of-function properties to
                            p53 and drive
                            early-onset malignancies. While the oncogenic role of mutant p53 is well established, its
                            impact
                            on adaptive immune function remains poorly understood.
                        </p>

                        <!-- Figure -->
                        <div class="flex justify-center">
                            <div class="max-w-4xl w-full">
                                <img src="images/projects/project6.png"
                                    class="w-full object-contain rounded-2xl shadow-md"
                                    alt="Immune dysregulation in Li-Fraumeni syndrome patients diagram">
                            </div>
                        </div>

                        <!-- Paragraph 2 -->
                        <p class="text-xs sm:text-base leading-relaxed text-gray-900">
                            In this project, I examined humoral immune responses using a Li-Fraumeni mouse model
                            carrying the
                            <em>Trp53R172H</em> mutation, equivalent to the <em>TP53R175H</em> mutation commonly found
                            in patients
                            (<a href="https://doi.org/10.64898/2026.01.21.700937" target="_blank"
                                class="text-blue-700 underline hover:text-blue-900 transition">
                                Koichi et al., 2026
                            </a>).
                            Following immunization with sheep red blood cells, I analyzed germinal center responses to
                            assess
                            B cell activation. <em>Trp53R172H</em> mice exhibited reduced B cell activation during the
                            early germinal
                            center reaction. These results suggest that gain-of-function p53 mutations impair early B
                            cell activation,
                            potentially contributing to immune dysfunction in Li-Fraumeni patients and influencing
                            susceptibility
                            to autoimmune response and therapeutic responses.
                        </p>

                    </div>


                </section>




            </div>
        </div>
    </main>

    <!-- FOOTER -->
    <div id="footer"></div>
    <script>
        loadHTML("footer", "common/footer.html");
    </script>
    <!-- Accordion -->
    <script>
        document.querySelectorAll(".accordion-btn").forEach(btn => {
            btn.addEventListener("click", () => {
                const panel = btn.nextElementSibling;
                const icon = btn.querySelector("span:last-child");

                panel.classList.toggle("hidden");
                icon.classList.toggle("rotate-45");
            });
        });
    </script>

</body>

</html>